These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15486118)

  • 1. Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation.
    Heidland A; Sebeková K; Frangiosa A; De Santo LS; Cirillo M; Rossi F; Cotrufo M; Perna A; Klassen A; Schinzel R; De Santo NG
    Heart; 2004 Nov; 90(11):1269-74. PubMed ID: 15486118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of advanced glycation end products in children with renal disease.
    Sebeková K; Podracká L; Blazícek P; Syrová D; Heidland A; Schinzel R
    Pediatr Nephrol; 2001 Dec; 16(12):1105-12. PubMed ID: 11793110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic value of advanced glycation end-products in chronic heart failure.
    Hartog JW; Voors AA; Schalkwijk CG; Scheijen J; Smilde TD; Damman K; Bakker SJ; Smit AJ; van Veldhuisen DJ
    Eur Heart J; 2007 Dec; 28(23):2879-85. PubMed ID: 17986469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma advanced glycation end products are decreased in obese children compared with lean controls.
    Sebeková K; Somoza V; Jarcusková M; Heidland A; Podracká L
    Int J Pediatr Obes; 2009; 4(2):112-8. PubMed ID: 18645732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD.
    Boschetto P; Campo I; Stendardo M; Casimirri E; Tinelli C; Gorrini M; Ceconi C; Fucili A; Potena A; Papi A; Ballerin L; Fabbri LM; Luisetti M
    Eur J Clin Invest; 2013 Jun; 43(6):562-9. PubMed ID: 23590548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?
    Sebeková K; Podracká L; Heidland A; Schinzel R
    Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis.
    Fragedaki E; Nebel M; Schupp N; Sebekova K; Völkel W; Klassen A; Pischetsrieder M; Frischmann M; Niwa T; Vienken J; Heidland A; Stopper H
    Nephrol Dial Transplant; 2005 Sep; 20(9):1936-43. PubMed ID: 15919695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced glycation end products and mortality in hemodialysis patients.
    Schwedler SB; Metzger T; Schinzel R; Wanner C
    Kidney Int; 2002 Jul; 62(1):301-10. PubMed ID: 12081592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study.
    Piroddi M; Palazzetti I; Quintaliani G; Pilolli F; Montaldi M; Valentina V; Libetta C; Galli F
    J Ren Nutr; 2011 Jul; 21(4):329-39. PubMed ID: 21193322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
    Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA
    Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease.
    Hartog JW; de Vries AP; Lutgers HL; Meerwaldt R; Huisman RM; van Son WJ; de Jong PE; Smit AJ
    Ann N Y Acad Sci; 2005 Jun; 1043():299-307. PubMed ID: 16037252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat.
    Davis KE; Prasad C; Vijayagopal P; Juma S; Adams-Huet B; Imrhan V
    Br J Nutr; 2015 Dec; 114(11):1797-806. PubMed ID: 26392152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased plasma sRAGE levels in COPD: influence of oxygen therapy.
    Gopal P; Rutten EP; Dentener MA; Wouters EF; Reynaert NL
    Eur J Clin Invest; 2012 Aug; 42(8):807-14. PubMed ID: 22288943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
    Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AGE formation blockade with aminoguanidine does not ameliorate chronic allograft nephropathy.
    Schmaderer C; Xing CJ; Anderson G; Hermans R; Lutz J; Heemann U; Baumann M
    Life Sci; 2011 Sep; 89(11-12):349-54. PubMed ID: 21763321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased levels of advanced glycation end-products in patients with Gilbert syndrome.
    Kalousová M; Novotny L; Zima T; Braun M; Vítek L
    Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(4):387-92. PubMed ID: 16309589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis.
    Yagmur E; Tacke F; Weiss C; Lahme B; Manns MP; Kiefer P; Trautwein C; Gressner AM
    Clin Biochem; 2006 Jan; 39(1):39-45. PubMed ID: 16321365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
    Axelsson J; Witasp A; Carrero JJ; Qureshi AR; Suliman ME; Heimbürger O; Bárány P; Lindholm B; Alvestrand A; Schalling M; Nordfors L; Stenvinkel P
    Am J Kidney Dis; 2007 Feb; 49(2):237-44. PubMed ID: 17261426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.